Categories: NewsPharmaceutical

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 109 new employees, in each case with a grant date of January 16, 2024, as equity inducement awards under the terms of the company’s 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as inducement material to the employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 14,206 shares of Madrigal’s common stock, and in the aggregate 32,788 time-based restricted stock units. All options granted have an exercise price of $243.92 per share, and vest as follows (i) 25% of the option shares will vest on the first anniversary of the date of grant and (ii) 6.25% of the option shares shall vest on each quarterly anniversary following the first anniversary of the date of grant. All restricted stock units granted vest in a 25% increment on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a liver-directed THR-β agonist oral therapy that is designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

Staff

Recent Posts

Massimo Group Signs Letter of Intent to Acquire 100% of AI technology company FST in Drive to Accelerate Its AI-Powered Mobility and Health Technology Strategy

GARLAND, Texas, Feb. 3, 2026 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO) ("Massimo" or the "Company"),…

6 minutes ago

Baysient Launches iDose® GEN7.0, Expanding Precision Dosing Platform to 16 Inflammatory Disease Indications

Next-Generation Decision Support Software Introduces Predictive Clinical Tools for Gastroenterology, Rheumatology, Dermatology, and PulmonologyFORT MYERS,…

6 minutes ago

From the Founders of Fitbit: Introducing Luffu, Your Guardian for Family Health & Safety

After making personal health accessible to millions with Fitbit, James Park and Eric Friedman announce…

6 minutes ago

Embla Medical hf: Interim Report Q4 and Full Year 2025

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full…

6 minutes ago

UAE Partners with Colossal Biosciences to Protect Biodiversity and Champion the Future of Life on Earth

The collaboration positions the UAE as a global leader in conservation, driving pioneering initiatives in…

6 minutes ago

Case Reports in Regrowth Announces Publication of Muhammad Qasim Observational Case Report and Invites Medical Review

New York, New York--(Newsfile Corp. - February 3, 2026) - Case Reports in Regrowth today…

36 minutes ago